Letters Smoking cessation and psychiatric symptoms

Authors’ reply to Davies

BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f7068 (Published 27 November 2013) Cite this as: BMJ 2013;347:f7068
  1. Kyla H Thomas, National Institute for Health Research doctoral fellow1,
  2. Richard M Martin, professor of clinical epidemiology12,
  3. Neil M Davies, postdoctoral research associate2,
  4. Chris Metcalfe, reader in medical statistics1,
  5. Frank Windmeijer, professor of econometrics3,
  6. David Gunnell, professor of epidemiology1
  1. 1School of Social and Community Medicine, University of Bristol, Bristol BS8 2PS, UK
  2. 2MRC Integrative Epidemiology Unit (IEU), University of Bristol, UK
  3. 3Department of Economics, Centre for Market and Public Organisation (CMPO), University of Bristol, UK
  1. kyla.thomas{at}bristol.ac.uk

We agree with Davies that further studies are needed before psychiatric safety concerns about varenicline can be laid to rest.1 2

We believe that our study provides reassuring evidence because we used validated outcomes for reporting suicide and non-fatal self harm and assessed the impact of confounding by indication using new and conventional methods. Because of its large …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe